269 related articles for article (PubMed ID: 21738045)
1. Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer.
Pradhan TS; Duan H; Katsoulakis E; Salame G; Lee YC; Abulafia O
Int J Gynecol Cancer; 2011 Aug; 21(6):1091-6. PubMed ID: 21738045
[TBL] [Abstract][Full Text] [Related]
2. Effect of hydronephrosis on survival in advanced stage cervical cancer.
Goklu MR; Seckin KD; Togrul C; Goklu Y; Tahaoglu AE; Oz M; Ertas IE
Asian Pac J Cancer Prev; 2015; 16(10):4219-22. PubMed ID: 26028076
[TBL] [Abstract][Full Text] [Related]
3. Lack of any impact of histopathology type on prognosis in patients with early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix.
Teke F; Yoney A; Teke M; Inal A; Urakci Z; Eren B; Zincircioglu SB; Buyukpolat MY; Ozer A; Isikdogan A; Unsal M
Asian Pac J Cancer Prev; 2014; 15(6):2815-9. PubMed ID: 24761906
[TBL] [Abstract][Full Text] [Related]
4. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study.
Waggoner SE; Darcy KM; Fuhrman B; Parham G; Lucci J; Monk BJ; Moore DH;
Gynecol Oncol; 2006 Dec; 103(3):853-8. PubMed ID: 16815535
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Survival in Patients With FIGO Stage IVB Cervical Cancer.
Sasano T; Mabuchi S; Kuroda H; Takahashi R; Kozasa K; Isohashi F; Yoshioka Y; Ogawa K; Kimura T
Int J Gynecol Cancer; 2016 Mar; 26(3):528-33. PubMed ID: 26825839
[TBL] [Abstract][Full Text] [Related]
6. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
7. Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?
Ayhan A; Aslan K; Bulut AN; Akilli H; Öz M; Haberal A; Meydanli MM
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():209-214. PubMed ID: 31325847
[TBL] [Abstract][Full Text] [Related]
8. Robotic Surgery in Patients With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: Survival Outcomes.
Siesto G; Romano F; Accardi A; Bulletti C; Iedà NP; Vitobello D
Int J Gynecol Cancer; 2016 Mar; 26(3):521-7. PubMed ID: 26825842
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
10. Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix.
Kim YB; Lee IJ; Kim SY; Kim JW; Yoon HI; Kim SW; Kim S; Kim YT; Suh CO; Kim GE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1323-8. PubMed ID: 19467800
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification.
Meng Q; Liu X; Wang W; Hou X; Lian X; Sun S; Yan J; Liu Z; Miao Z; Hu K; Zhang F
Radiat Oncol; 2019 Dec; 14(1):228. PubMed ID: 31842919
[TBL] [Abstract][Full Text] [Related]
13. Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.
Chiantera V; Rossi M; De Iaco P; Koehler C; Marnitz S; Ferrandina G; Legge F; Parazzini F; Scambia G; Schneider A; Vercellino GF
Int J Gynecol Cancer; 2014 Jun; 24(5):916-22. PubMed ID: 24442006
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.
Chan JK; Loizzi V; Burger RA; Rutgers J; Monk BJ
Cancer; 2003 Feb; 97(3):568-74. PubMed ID: 12548598
[TBL] [Abstract][Full Text] [Related]
15. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent.
Narayan K; Fisher RJ; Bernshaw D; Shakher R; Hicks RJ
Int J Gynecol Cancer; 2009 Jul; 19(5):912-8. PubMed ID: 19574784
[TBL] [Abstract][Full Text] [Related]
16. The Number of Positive Pelvic Lymph Nodes and Multiple Groups of Pelvic Lymph Node Metastasis Influence Prognosis in Stage IA-IIB Cervical Squamous Cell Carcinoma.
Liu Y; Zhao LJ; Li MZ; Li MX; Wang JL; Wei LH
Chin Med J (Engl); 2015 Aug; 128(15):2084-9. PubMed ID: 26228223
[TBL] [Abstract][Full Text] [Related]
17. Impact of hydronephrosis on outcome of stage IIIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study.
Rose PG; Ali S; Whitney CW; Lanciano R; Stehman FB
Gynecol Oncol; 2010 May; 117(2):270-5. PubMed ID: 20181381
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
19. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
20. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
